Drug interactions
Encorafenib + Sunitinib
Severity: Major
Encorafenib and Sunitinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both sunitinib and encorafenib are associated with QT interval prolongation. Concurrent use may add to the risk of clinically significant arrhythmia, especially in patients with electrolyte disturbance or cardiac disease.
What this interaction means in plain words
Encorafenib and Sunitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Encorafenib belongs to Oncology; Sunitinib belongs to Oncology.
Why it happens
Additive pharmacodynamic QT prolongation.
What to do
Avoid the combination if an alternative exists. Otherwise obtain baseline and periodic ECGs, correct electrolytes, and reduce or hold therapy if the QTc becomes markedly prolonged.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Sunitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Sunitinib
- Adagrasib + Sunitinib Major
- Amiodarone + Sunitinib Major
- Amisulpride + Sunitinib Major
- Anagrelide + Sunitinib Major
- Apalutamide + Sunitinib Major
- Arsenic trioxide + Sunitinib Major
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Sunitinib?
MediHelp rates the interaction as major. Encorafenib and Sunitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both sunitinib and encorafenib are associated with QT interval prolongation. Concurrent use may add to the risk of clinically significant arrhythmia, especially in patients with electrolyte disturbance or cardiac disease.
How serious is the interaction between Encorafenib and Sunitinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination if an alternative exists. Otherwise obtain baseline and periodic ECGs, correct electrolytes, and reduce or hold therapy if the QTc becomes markedly prolonged.
What other medicines interact with Sunitinib?
MediHelp also lists interactions of Sunitinib with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Sunitinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
